Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Income from Non-Controlling Interests (2019 - 2025)

Historic Income from Non-Controlling Interests for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$2.2 million.

  • BridgeBio Pharma's Income from Non-Controlling Interests rose 90.33% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.6 million, marking a year-over-year decrease of 1545.92%. This contributed to the annual value of -$7.6 million for FY2024, which is 2451.99% up from last year.
  • Per BridgeBio Pharma's latest filing, its Income from Non-Controlling Interests stood at -$2.2 million for Q3 2025, which was up 90.33% from -$1.9 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Income from Non-Controlling Interests peaked at $7.3 million during Q2 2022, and registered a low of -$8.0 million during Q1 2021.
  • In the last 5 years, BridgeBio Pharma's Income from Non-Controlling Interests had a median value of -$2.5 million in 2023 and averaged -$2.7 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Income from Non-Controlling Interests soared by 22743.63% in 2022, and later crashed by 13842.68% in 2023.
  • BridgeBio Pharma's Income from Non-Controlling Interests (Quarter) stood at -$5.1 million in 2021, then surged by 41.65% to -$3.0 million in 2022, then rose by 26.82% to -$2.2 million in 2023, then dropped by 7.29% to -$2.3 million in 2024, then increased by 6.2% to -$2.2 million in 2025.
  • Its Income from Non-Controlling Interests was -$2.2 million in Q3 2025, compared to -$1.9 million in Q2 2025 and -$2.2 million in Q1 2025.